77.1%
anti-PD-(L)1anti-programmed death-ligand 1 (PD-(L)1)Gustave RoussyREISAMICsolid or hematologic malignanciesadvanced or metastatic canceradvanced/metastatic cancer
…table risk of severe and fatal irAEs following a single dose of anti-PD-(L)1 therapy in patients with advanced/metastatic cancer. The absenc…